Azenta 관리

관리 기준 확인 0/4

Azenta CEO는 John P. Marotta, Sep2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 € 605.72K 가치에 해당하는 회사 주식의 0.031% 직접 소유합니다. 605.72K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 0.8 년입니다.

주요 정보

John P. Marotta

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.03%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

CEO

John P. Marotta (43 yo)

less than a year

테뉴어

Mr. John P. Marotta is President & CEO of Azenta, Inc. from September 9, 2024. Mr. Marotta serves as Executive in Residence at Patient Square Capital, LP since joining the firm in March 16, 2023. He levera...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jason Joseph	Senior VP	13.7yrs	US$1.44m	0.25% € 4.9m
John P. Marotta	President & CEO	less than a year	데이터 없음	0.031% € 605.7k
Lawrence Lin	Executive VP & CFO	no data	데이터 없음	데이터 없음
Violetta Hughes	VP & Chief Accounting Officer	1.3yrs	데이터 없음	0.0010% € 20.0k
Michael Paulo	VP and Chief Information & Digital Officer	7.3yrs	데이터 없음	데이터 없음
Yvonne Perron	Vice President of Financial Planning & Analysis and Investor Relations	no data	데이터 없음	데이터 없음
John O'Brien	Senior Vice President of Corporate Development	14.5yrs	데이터 없음	데이터 없음
Olga Pirogova	Senior VP & Chief HR Officer	1.3yrs	데이터 없음	0.0024% € 46.4k
J. Woodward	Senior Vice President of Global Quality & Regulatory	15yrs	데이터 없음	데이터 없음
Ginger Zhou	Senior VP and GM of the Genewiz Multiomics & Synthesis Solutions	5.5yrs	데이터 없음	0.021% € 416.8k
David Wang	Senior VP & GM of Sample Management Solutions	1.8yrs	데이터 없음	0.014% € 277.7k
Herman Cueto	Employee Advisor	no data	데이터 없음	0.0066% € 129.4k

1.8yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: BA3 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Tina Nova	Independent Director	1.8yrs	US$207.50k	0.013% € 263.2k
Michael Rosenblatt	Independent Director	6.2yrs	US$260.00k	0.029% € 565.6k
Martin Madaus	Independent Director	less than a year	데이터 없음	0.016% € 321.1k
Didier Hirsch	Independent Director	less than a year	데이터 없음	0.0076% € 150.2k
Alan Malus	Independent Director	no data	데이터 없음	0.0022% € 43.1k
Edward Bousa	Independent Director	less than a year	데이터 없음	0.0054% € 106.9k
Robyn Davis	Independent Vice Chair of the Board	11.4yrs	US$278.75k	0.065% € 1.3m
William Cornog	Independent Director	no data	데이터 없음	0.032% € 639.9k
Erica McLaughlin	Independent Director	4.6yrs	US$273.75k	0.028% € 555.9k
Frank Casal	Independent Chairman	3yrs	US$275.00k	0.021% € 407.3k
Quentin Koffey	Independent Director	no data	데이터 없음	0.0022% € 43.1k

0.8yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: BA3 의 이사회는 경험(평균 재직 기간 0.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Azenta 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. Announces Management Changes

Stephen Schwartz to Retire as CEO of Azenta, Inc

High number of new directors

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Recent updates

Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023)

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta, Inc. Announces Management Changes

Forecast to breakeven in 2026

New minor risk - Share price stability

No longer forecast to breakeven

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Second quarter 2024 earnings released: US$2.47 loss per share (vs US$0.029 loss in 2Q 2023)

Stephen Schwartz to Retire as CEO of Azenta, Inc

Now 22% overvalued

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

Now 21% overvalued

New major risk - Revenue and earnings growth

New minor risk - Profitability

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings released: US$0.19 loss per share (vs US$0.15 loss in FY 2022)

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Politan Capital Provides Information to the Shareholders

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

New minor risk - Insider selling

Insider recently sold €369k worth of stock

Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.094 loss in 3Q 2022)

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.024 loss in 2Q 2022)

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.038 profit in 1Q 2022)

Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023

Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd.

Azenta, Inc. Announces Election of Directors

Azenta, Inc., Annual General Meeting, Jan 31, 2023

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2021)

Azenta Announces Board Resignations

Azenta, Inc. to Report Q4, 2022 Results on Nov 14, 2022

Azenta, Inc. Announces Matthew McManus Would No Longer Serve as the Companys Chief Operating Officer Effective as of October 14, 2022

Azenta, Inc. (NasdaqGS:AZTA) acquired B Medical Systems S.à R.L. from Navis Capital Partners.

Executive VP & COO recently bought €500k worth of stock

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.53 profit in 3Q 2021)

Azenta, Inc. Provides Earnings Guidance for the Fourth Quarter Fiscal 2022

Azenta, Inc. (NasdaqGS:AZTA) entered into an agreement to acquire B Medical Systems S.à R.L. for approximately €460 million.

Azenta, Inc. Provides Earnings Guidance for the Third Fiscal Quarter Ended June 30, 2022

Azenta, Inc.(NasdaqGS:AZTA) dropped from Russell 3000E Growth Index

Azenta, Inc. announced delayed 10-Q filing

Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.32 profit in 2Q 2021)

Azenta, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Now 21% undervalued after recent price drop

Azenta, Inc. to Report Q2, 2022 Results on May 03, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Azenta, Inc. Provides Earnings Guidance for the Second Quarter Fiscal Year 2022

Azenta, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2023

Azenta, Inc.(NasdaqGS:AZTA) dropped from NASDAQ Composite Index

Upcoming dividend of US$0.10 per share

Independent Director recently sold €282k worth of stock

Full year 2021 earnings released: US$0.39 loss per share (vs US$0.88 profit in FY 2020)